vs
ENERPAC TOOL GROUP CORP（EPAC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
ENERPAC TOOL GROUP CORP的季度营收约是再鼎医药的1.1倍（$144.2M vs $127.1M），再鼎医药同比增速更快（17.1% vs -0.7%），ENERPAC TOOL GROUP CORP自由现金流更多（$13.3M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.1%）
恩派克工具集团前身为Actuant公司，成立于1910年，总部位于美国威斯康星州梅诺莫尼福尔斯，是一家历史悠久的工业工具企业，其普通股在纽约证券交易所上市，股票代码为EPAC。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
EPAC vs ZLAB — 直观对比
营收规模更大
EPAC
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出17.8%
-0.7%
自由现金流更多
EPAC
多$40.0M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $144.2M | $127.1M |
| 净利润 | $19.1M | — |
| 毛利率 | 50.7% | 51.0% |
| 营业利润率 | 19.8% | -54.6% |
| 净利率 | 13.3% | — |
| 营收同比 | -0.7% | 17.1% |
| 净利润同比 | -11.9% | — |
| 每股收益（稀释后） | $0.36 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPACZLAB
| Q4 25 | $144.2M | $127.1M | ||
| Q3 25 | $167.5M | $115.4M | ||
| Q2 25 | $158.7M | $109.1M | ||
| Q1 25 | $145.5M | $105.7M | ||
| Q4 24 | $145.2M | $108.5M | ||
| Q3 24 | $158.7M | $101.8M | ||
| Q2 24 | $150.4M | $100.1M | ||
| Q1 24 | $138.4M | $87.1M |
净利润EPACZLAB
| Q4 25 | $19.1M | — | ||
| Q3 25 | $28.1M | $-36.0M | ||
| Q2 25 | $22.0M | $-40.7M | ||
| Q1 25 | $20.9M | $-48.4M | ||
| Q4 24 | $21.7M | — | ||
| Q3 24 | $24.4M | $-41.7M | ||
| Q2 24 | $25.8M | $-80.3M | ||
| Q1 24 | $17.8M | $-53.5M |
毛利率EPACZLAB
| Q4 25 | 50.7% | 51.0% | ||
| Q3 25 | 50.1% | 59.5% | ||
| Q2 25 | 50.4% | 60.6% | ||
| Q1 25 | 50.5% | 63.6% | ||
| Q4 24 | 51.4% | 61.5% | ||
| Q3 24 | 48.8% | 64.1% | ||
| Q2 24 | 51.8% | 64.9% | ||
| Q1 24 | 51.6% | 61.4% |
营业利润率EPACZLAB
| Q4 25 | 19.8% | -54.6% | ||
| Q3 25 | 23.8% | -42.3% | ||
| Q2 25 | 20.0% | -50.3% | ||
| Q1 25 | 21.2% | -53.3% | ||
| Q4 24 | 21.4% | -62.6% | ||
| Q3 24 | 18.9% | -66.6% | ||
| Q2 24 | 22.2% | -76.0% | ||
| Q1 24 | 21.3% | -80.7% |
净利率EPACZLAB
| Q4 25 | 13.3% | — | ||
| Q3 25 | 16.8% | -31.2% | ||
| Q2 25 | 13.9% | -37.3% | ||
| Q1 25 | 14.4% | -45.8% | ||
| Q4 24 | 15.0% | — | ||
| Q3 24 | 15.4% | -40.9% | ||
| Q2 24 | 17.1% | -80.2% | ||
| Q1 24 | 12.9% | -61.4% |
每股收益（稀释后）EPACZLAB
| Q4 25 | $0.36 | $-0.05 | ||
| Q3 25 | $0.51 | $-0.03 | ||
| Q2 25 | $0.41 | $-0.04 | ||
| Q1 25 | $0.38 | $-0.04 | ||
| Q4 24 | $0.40 | $-0.09 | ||
| Q3 24 | $0.44 | $-0.04 | ||
| Q2 24 | $0.47 | $-0.08 | ||
| Q1 24 | $0.33 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $139.0M | $689.6M |
| 总债务越低越好 | $188.8M | — |
| 股东权益账面价值 | $431.1M | $715.5M |
| 总资产 | $818.1M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资EPACZLAB
| Q4 25 | $139.0M | $689.6M | ||
| Q3 25 | $151.6M | $717.2M | ||
| Q2 25 | $140.5M | $732.2M | ||
| Q1 25 | $119.5M | $757.3M | ||
| Q4 24 | $130.7M | $779.7M | ||
| Q3 24 | $167.1M | $616.1M | ||
| Q2 24 | $132.4M | $630.0M | ||
| Q1 24 | $153.7M | $650.8M |
总债务EPACZLAB
| Q4 25 | $188.8M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $191.3M | — | ||
| Q1 25 | $192.5M | — | ||
| Q4 24 | $193.8M | — | ||
| Q3 24 | $195.0M | — | ||
| Q2 24 | $196.3M | — | ||
| Q1 24 | $245.5M | — |
股东权益EPACZLAB
| Q4 25 | $431.1M | $715.5M | ||
| Q3 25 | $433.7M | $759.9M | ||
| Q2 25 | $438.2M | $791.7M | ||
| Q1 25 | $406.0M | $810.8M | ||
| Q4 24 | $398.0M | $840.9M | ||
| Q3 24 | $392.0M | $667.7M | ||
| Q2 24 | $365.8M | $704.2M | ||
| Q1 24 | $336.9M | $762.2M |
总资产EPACZLAB
| Q4 25 | $818.1M | $1.2B | ||
| Q3 25 | $827.9M | $1.2B | ||
| Q2 25 | $828.1M | $1.2B | ||
| Q1 25 | $776.6M | $1.2B | ||
| Q4 24 | $775.4M | $1.2B | ||
| Q3 24 | $777.3M | $985.3M | ||
| Q2 24 | $749.5M | $987.4M | ||
| Q1 24 | $769.3M | $988.4M |
负债/权益比EPACZLAB
| Q4 25 | 0.44× | — | ||
| Q3 25 | 0.44× | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $13.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | 9.2% | -21.0% |
| 资本支出强度资本支出/营收 | 1.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.84× | — |
| 过去12个月自由现金流最近4个季度 | $102.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流EPACZLAB
| Q4 25 | $16.0M | $-26.0M | ||
| Q3 25 | $55.3M | $-32.0M | ||
| Q2 25 | $39.9M | $-31.0M | ||
| Q1 25 | $7.5M | $-61.7M | ||
| Q4 24 | $8.6M | $-55.8M | ||
| Q3 24 | $44.4M | $-26.8M | ||
| Q2 24 | $30.3M | $-42.2M | ||
| Q1 24 | $13.3M | $-90.1M |
自由现金流EPACZLAB
| Q4 25 | $13.3M | $-26.7M | ||
| Q3 25 | $52.3M | $-35.0M | ||
| Q2 25 | $35.1M | $-33.9M | ||
| Q1 25 | $1.8M | $-63.2M | ||
| Q4 24 | $2.8M | $-58.4M | ||
| Q3 24 | $37.9M | $-28.2M | ||
| Q2 24 | $28.5M | $-42.9M | ||
| Q1 24 | $11.7M | $-91.1M |
自由现金流率EPACZLAB
| Q4 25 | 9.2% | -21.0% | ||
| Q3 25 | 31.2% | -30.4% | ||
| Q2 25 | 22.1% | -31.1% | ||
| Q1 25 | 1.2% | -59.9% | ||
| Q4 24 | 1.9% | -53.8% | ||
| Q3 24 | 23.9% | -27.7% | ||
| Q2 24 | 18.9% | -42.9% | ||
| Q1 24 | 8.5% | -104.5% |
资本支出强度EPACZLAB
| Q4 25 | 1.9% | 0.5% | ||
| Q3 25 | 1.8% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 3.9% | 1.5% | ||
| Q4 24 | 4.0% | 2.4% | ||
| Q3 24 | 4.1% | 1.3% | ||
| Q2 24 | 1.2% | 0.7% | ||
| Q1 24 | 1.1% | 1.1% |
现金转化率EPACZLAB
| Q4 25 | 0.84× | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 1.81× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 0.75× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPAC
| Transferred At Point In Time | $126.0M | 87% |
| Other | $12.1M | 8% |
| Other Operating Segment | $6.1M | 4% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
